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We report hat the rat~3-adrener~c receptor (B3-AR) gene has an intron. The intron starts with an in-frame stop codon with the result that unspliced 
transcripts will encode a C-terminal truncated protein. The reported protein sequences of mouse and human j33-AR were both deduced from 
genomic DNA sequences. Given the heterogeneity at the C-termini of the otherwise highly similar rat, mouse and human sequences, we discuss 
the intriguing possibility that the p3-AR gene of the latter two species also contain an intron near the extremity of the open reading frame. A 
,&adrenergic receptor (B-AR) cDNA we have cloned from rat colonic tissue which has a sequence ssentially identical to that previously reported 
for the rat adipose /33-AR cDNA [(1991) J. Chem. 266, 240.531, encodes the spliced version of the j?3-AR. 
~3-Adrener#c receptor; Intron; Polymerase chain reaction 
I. INTRODUCTION 
Activation of p-adrenergic receptors @-AR) by ag- 
onists leads to a stimulation of adenylyl cyclase through 
the interaction of the receptor with a G-protein termed 
G, (stimulatory guanine nucleotide binding protein) [l]. 
The sub-classification of B-AR into Bl and j?2 subtypes 
is based on the relative potency of the naturally occur- 
ring catecholamines, epinephrine and norepinephrine. 
B-1 responses are equally sensitive to these two agonists; 
82 responses are more potently stimulated by epineph- 
rine [2,3]. During the past few years, evidence has accu- 
mulated indicating that, in addition to the /Il- and /?2- 
adrenoceptors, a further subtype may exist. The most 
prominent example is the rat adipocyte p-adrenoceptor, 
originally classified as typically Bl [3]. However, phar- 
macological studies have shown incong~ities with re- 
spect to this characterization; (i) unexpected low poten- 
cies of non-selective [4] and @-selective [5] antagonists, 
and (ii) the failure to confirm the /3X -receptor properties 
with non-catecholamine agonists [6]. In the rat, besides 
the adipose tissues [3], atypical #I-adrenoceptors have 
been found in the heart [7], and the colon [8,9]. Re- 
cently, a correlation between colonic motility inhibition 
and adipocyte lipolysis was found for phenylethanolam- 
inotetralines, selective inhibitors of colonic motility, in- 
dicating that the rat colonic and adipose atypical p re- 
ceptors are similar [lo]. 
The existence of these three subtypes has now been 
confirmed by molecular biology techniques [1 11. Cell 
lines expressing the different subtypes of the cloned j$- 
AR genes have been constructed to study structure- 
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function relationships. In contrast to previous observa- 
tions with CHO cells transfected with /Q- and BZAR 
genes, there were noticeable pharmacological differ- 
ences between the /?3-ARs expressed on transfected 
CHO cells and the atypical ~-adrenoceptors 112-l 51. 
That raised questions concerning the molecular diver- 
sity of atypical j&adrenoceptor proteins, and/or the 
specificity of the transduction process in CHO cells. We 
report here the cloning of the rat colonic atypical B-AR 
cDNA and we confirm, at the molecular level, the sim- 
ilarity between the adipose and colonic atypical fi-ARs. 
In addition, we have looked for the presence of intron(s) 
in the rat p3-AR gene and demonstrate that: (i) both the 
rat adipocyte and colonic cDNAs represent a spliced 
form of the BZAR gene, and (ii) the spliced and unspli- 
ted transcripts will encode receptor proteins with differ- 
ent C-termini. 
2. MATERIALS AND METHODS 
2.1. Construction of a cDNA library 
Total RNA was extracted from colonic tissue by using the acid 
guanidinium isothiocyanate phenol chloroform method [16]. Poly(A) 
RNA was isolated from total RNA by oligo(dT)-~IIulose chromatog- 
raphy as described by Aviv and Leder 1171. The cDNA library was 
constructed using the primer-adapter procedure [IS] and the pTZl8 
vector (Pharmacia). Approximately 1.5 x IO6 primary recombinants 
were analyzed as described by Grunstein and Hogness [19]. DNA 
sequences were determined by the method of Sanger [20]. 
2.2. Polymerase chain reaction fPCR) 
Degenerated primers (D3 and D6) derived from nucleotide se- 
quences corresponding to transmembrane segments III and VI of 
G-protein-coupled receptors (see Fig. 1) were used to amplify rat 
genomic DNA as described by Llbert &?I]. Amplified DNAs were 
cloned into pTZ19 vector (Pharmacia) and the recombinant clones 
were analyzed by in situ colony hybridization using 3ZP-labeied ol- 
igonucleotides pecific for fil-. /32- and B3-AR genes. 
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CCACAGCTGACTTGGTAGTGGGACTCCTCGTAATGCCACCAGGGGCCACATTGGCGCTGA 
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158 VWIVSATVSFAPIMSOWWRV 177 
530 
178 
590 
198 
TAGGGGCAGACGCTGAGGCGCAAGAGTGTCACTCCAATCCGCGCTGCTGTTCCTTTGCCT 
GADAEAQEC HSNPRCC S F A S 
CCAATATGCCCTACGCGCTGCTCTCCTCCTCCGTCTCCTTCTACCTTCCCCTCCTTGTGA 
NMPYALLSSSVSFYLPLLVM 
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CTGCCACAGTCGGGACACCCACGGCATCGGATGGAGTGCCCTCCTGCGGGCGGCGGCCTG 
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1010 CCTTCAACCCGCTCATCTACTGCCGCAGCCCGGACTTTCGCGACGCCTTCCGTCGTCTTC 1069 
338 FNPLIYCRS PDFRDAFRRLL 357 
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TGTGCAGCTACGGTGGCCGTGGACCGGAAGAGCCACGCGTGGTCACCTTCCCAGCTAGCC 
C SYGGRGP EEPRVVTF P A S P 
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CTGTTGCGTCCAGGCAGAACTCACCGCTCAACAGGTTTGATGGCTATGAAGGTGAGCGTC 
VASRQN SPLNRFDG YEGERP 
P_r_l_m_e_r_B_ _ 
1189 
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1190 CATTTCCCACATGAAGGACCATGGAGATCTAGCAAGGAGCCTGACTTCTGGAGAAATTTT 1249 
398 F P T * 417 
1250 TTTTTAAGACAGAAAGACAAGCAACGTCCATGGATGCAAACTTTTTATACAGCCCTTGAT 
1310 TTCTGCTCAGAGTGAGTTCCCAGGAACCGCAACTCTCCAGAACCAATGACTAGACCACAG 
1370 AATGTAAAGGGGP~TCTTACCAAATGGGTTTTACCATCTTCTCTCTCTTTCTGAGAGAC 
1430 GTTGTCTAGGATCCACCTTGAACTTCGCTACTACCTCAGCCGCCGGGATATCAGGCCACC 
1490 CGTGCTTGAC~CCCTGGGAGGAGCTGCGTTCCCACCACCACCCTGCTTATTATGTTTGT 
1550 GCTGGATGCTTAGGGCTAAGllAAGCACCCTTACCTACCTCTCTTCCTAC~C~TCC~A 
1610 CCCCATGAATGACTTTTGTCTCCACAAATCACTCTGTCTCCAGGTTCTGTGTTCCCAGTC 
1670 TCTGTGTCTCTGGTTAGTTGGAAAGCAGG~CCCGGCGGGGGAGGCGGGGGAGGGGGGG 
1730 AACGACCAAGTTTGAGGTTTTGTCCCTGGCTCCTCACTACAGCTCTCTAAACATCATCTT 
1790 GGACCATCTCTCACAATAGGCACAAAACAGCTCTAATCTACCTCACTCTTAGGACTTCAA 
1850 GGTTTGGGAGAAATTCCAGGGTTCCTGGGAAGAAGTCAAACCATTGGAATGGGTCCCTTT 
1910 TCCACTTAAAATCAAATTAATAAATATTATTATGTGAA 1957 
1309 
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1429 
1489 
1549 
1609 
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1789 
1849 
1909 
CGCGACACGAGATGGCTCCGTGGCCTCACAAAAACGGCTCAC~CGGCTCTC~GCTTTCTGGTCAGACG 49 
MAPWPHKNGSLAFWSDA 17 
Fig. 1. Nucleotide and nredicted amino acid sequences of rat colonic B3-AR cDNA. The presumntive transmembrane domains are underlined. 
Primers -used for PCR are marked by dashed lines-with arrows. 
cDNAs were reverse transcribed from total RNA then treated with genomic DNA and cDNAs using the Taq DNA polymerase. Cycle 
DNAse prior to subjection to PCR. Specific primers (A and B) derived conditions were 1.5 min at 93°C 1.5 min at 60°C and 2 min at 72°C. 
from the B3-AR cDNA (Fig. 1) were used to amplify (30 cycles) rat Aliquots of the amplified DNA were analyzed by Southern blot. 
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b3-AR-Rat / cDNA .VFIALN~LGYAI~SAFNPLIY~R~PDFRDAFRRLL~~Y~GGR~G . . . . . 
b3-AR.Mouse/Gene 
.t~iA~bb~~;,iHA~~~Vi~~~~~~~~~~~~~~~~~~~~~~ 
: : : : : : : : : : : :: : : : : : : : : : : : * : : 
b3-AR.Human/Gene .A;~&&iLGYANSAFNPLIYCRSPDFRSiFRRiLCRC;RiL 
b3-AR.Rat f cDNA PEEp-- -4WVTFPASPVASRQNSPLNR'FDGYEGERPFpT 
b3-AR.Mouse/Gene ;;;;__- 
_KAtiF~A~~tEAR~SP~~~K 
b3-AR.Human/Gene ~PH~CAAA~PALF~SGVPAA~S~T~AQ~~LCQRLDG 
Fig. 2. Aligment of rat, mouse and human C-terminalB3-ARs. Doubled dots indicate identities. The arrow shows the C-terminus of the rat p3-AR 
deduced from the genomic sequence. 
3. RESULTS AND DISCUSSION 
3.1. PCR, cDNA cloning and sequencing 
Rat genomic DNA was prepared and amplified by 
PCR using degenerated primers matching the trans- 
membrane domains III and VI of G-protein-coupled 
receptors as described elsewhere [21]. The resulting am- 
plified DNAs were cloned into the pTZ19 vector and 
the recombinant clones containing B-AR-related DNA 
sequences were identified by in situ colony hybridiza- 
tion. Nucleotide sequence determination revealed that 
only Bl-, 82-, and /?3-AR gene fragments were ampli- 
fied, with no other B-AR related DNA sequence being 
detectable. These fragments were used to isolate/31-, 82- 
and B3-AR cDNAs from a rat colonic cDNA library. 
Fig. 1 shows the 1,957 nu~leotide sequence of a p3-AR 
cDNA. The putative encoded protein shows the classi- 
cal structural features of G-protein-coupled receptors 
and an almost complete identity with the adipose 83- 
a 
Iu: ) 
4- 
,2- 
b 
61 
121 
101 
241 
301 
361 
421 
481 
541 
AR 1121. These results confirm the similarity of adipose 
and colonic atypical B-ARs. 
3.2. PCR identification, cloning and sequencing of an 
intron 
The rat and mouse B3-AR proteins are almost identi- 
cal (95%) but differ at the C-terminal end, a region 
shown to be important for /?2-AR desensitization [22]. 
The mouse protein [ 151 is 12 amino acids shorter than 
the rat receptor (Fig. 2). Considering that the mouse 
/?3-AR was deduced from a genomic sequence, whereas 
the rat B3-AR is encoded by the cDNA, we thought that 
the difference could be related to a splicing event rather 
than a difference between species. In order to investigate 
the rat /33-AR genomic sequence, we performed PCR 
experiments with rat genomic DNA and rat colonic 
eDNA. A pair of oligonucleotides matching the cDNA 
as shown in Fig. 1 (primers A and B) served as primers. 
NSAFNPLIYCRSPDFRDAFR 
GTCGTCTTCTGTGCAGCTACGGTC;GCCGTGGACCGGAA(CCTTCC 
RLLCSYGGRGPEEPRVVTFP 
t& CAGCTAGCCCTGTTGCGTCCAGGCAGAACTCACCGCTCAACA TAGGCGACGCAGGCAG 
ASPVASRQNSPLNR* 
AGGACTGGAGTCTGGGTGGGCTCTGTCTCTATTTT 
GGAGAAGGTGTAGACAGGGCTTTTGTCTCGAGAGGACAGAAAAGGAGTAAGAACAGAATC 
GGGATCTAGGGCCCTTCCTTTTATTGGATCCAATCCCTGGGTCTGAGGCAAAGGAGGAAA 
GGGAAATTTGTTCACCTTGGGACCAGGTGAGCCCCACAGGTTTCTGCCAGCAGGTTTCTG 
ACCTCTCTGGTTGCCTCTAGTTTGA;ATCTT~TAGTTCTATTCTC~G~~CCAGGTAT 
CACT~CTTGTCT~~TC~TA~CAG~T~ACATGT~GTCCTCT~~~GT 
TCCGCTTTCTTTCAA TTTGATGGCTATGAAGG’TG~GC?jTC&?‘&&AC~T~~G 
FDGYEGERPFPT* 
60 
120 
180 
240 
300 
360 
420 
480 
540 
599 
Fig. 3. (a) Southern blot analysis. Lane A, amplified DNA fragments from genomic DNA; lane B, amplified DNA fragments from cDNAs. 
(b) Nucleotide sequence of the B3-AR DNA segment amplified from genomic DNA. Primers used are marked by dashed lines with arrows. The 
arrows indicate the exon-intron junctions. 
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The amplified DNA fragments were analyzed by South- 
ern blot (Fig. 3a). From the cDNA, a 207 bp amplified 
DNA fragment was obtained as expected (Fig. 3a, lane 
B), whereas a larger fragment was amplified from the 
genomic DNA (Fig. 3a, lane A). The amplified genomic 
fragment was cloned and sequenced (Fig. 3b). 
The rat ~!?3-AR gene has an additional 393 bp located 
between positions 1,164-l ,165 of the cDNA. This in- 
tron starts with a stop codon which interrupts the ORF 
of the cDNA, shortening by 12 amino acids the C- 
terminus of the protein encoded by the cDNA. Interest- 
ingly, from the rat and mouse P3-AR genomic se- 
quences almost identical proteins are deduced sharing 
the same C-terminus. Moreover, the homology of se- 
quence between both genes is maintained (87%) further 
downstream from the stop codon (Fig. 2), indicating the 
probability of an intron in the mouse /?3-AR gene as 
well. 
This result raises interesting questions. 
(i) What is the biological significance of this intron 
which may give rise to spliced variants encoding differ- 
ent forms of the receptor? The use of alternate splicing 
to generate different forms of G-protein-coupled recep- 
tors was first described for the dopamine D, receptor 
[23] and more recently for the mouse somatostatin re- 
ceptor [24]. We are presently investigating the presence 
of spliced variants in rat tissues. 
(ii) What are the pharmacological differences be- 
tween the two forms of the rat/33-AR? The C-terminus 
of thej?2-AR has been shown to be involved with recep- 
tor desensitization through the phosphorylation of hy- 
droxyl amino acid sites [22]. At least one phosphoryla- 
tion site is present among the 12 amino acids missing at 
the C-terminus of the receptor encoded by genomic se- 
quences. We are also investigating the pharmacological 
properties of these two possible forms of rat /?3-AR. 
(iii) What of the human/?3-AR, the sequence of which 
was deduced from genomic sequences. In spite of high 
homologies between the human, rat and mouse recep- 
tors, their C-terminal sequences are quite different (Fig. 
2). It is clearly important to dispose of a human /?3-AR 
cDNA to be able to determine the protein sequence of 
/33-AR actually expressed in tissues. As for the rat /33- 
AR gene, two forms of receptor might exist due to the 
presence of an intron and splicing events. This would 
probably explain the pharmacological differences found 
between the human P3-AR expressed on CHO cells 
transfected with the /?3-AR and atypical B-AR from 
adipose and colonic tissues [14]. 
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